Temgesic 0.2 mg/1 ml Sublingual Tablets. Injection
PDF Leaflet Revision Date: 02 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Moderate to severe pain management.
Dosage (summary)
0.3 to 0.6 mg every 6-8 hours for adults.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; may cause neonatal withdrawal syndrome. Not recommended for breastfeeding.
Key Drug Interactions
- Benzodiazepines
- Serotonergic medicines
- CNS depressants
Contraindications
- Hypersensitivity to buprenorphine
- Severe hepatic insufficiency
- Impaired respiratory function
- Acute asthma
Common side effects
- Sedation
- Dizziness
- Nausea
- Hypotension
Counselling Points
- Avoid alcohol
- Monitor for respiratory depression
- Discuss withdrawal strategy before treatment
Serious warnings
- Risk of respiratory depression
- Potential for drug dependence
- Serotonin syndrome risk
Important Disclaimer
The Temgesic 0.2 mg/1 ml Sublingual Tablets. Injection professional information leaflet below is the property of Adcock Ingram Critical Care and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
